There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. But it could get much more crowded in the future. And it's little wonder why, given analysts project that the obesity drug market could be worth $200 billion by 2031. It's a mammoth growth opportunity that can jump-start a company's sales and profits. Before drugs are approved, investors can gain insights into just how promising a GLP-1 drug is from the resu ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth has reached a deal with drug makers Ely Lilly and Novo Nordisk which it said will bring prices down for employers and their workers."This solution is really focused towards clients that aren't covering it today, and what it allows us to do is one, to bring it on at a reduced price for the plan sponsor, but also cap ...

Summary ⚈ HIMS stock surged up to 45% after announcing a partnership with Novo Nordisk to offer Wegovy through its platform. The American firm will now offer prescriptions for the drug starting at $599 per month via NovoCare Pharmacy. Previously, Wegovy was available only through local pharmacies or from Novo's NovoCare Pharmacy program. The partnership unlocks a potentially massive new revenue stream for Hims & Hers, which has been steadily growing its subscription-based health offerings. By integrating We ...